Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659800 | 0.83 | P2RX7 (0.40) | HPGDALDH1A1P2RX7 | |
| SCHEMBL23336653 | 0.82 | KDM4A (0.39) | MEN1KMT2AMEP1BL3MBTL1NPC1 | |
| SCHEMBL29840257 | 0.82 | KDM4A (0.39) | MEN1KMT2AMEP1BL3MBTL1NPC1 | |
| SCHEMBL3394171 | 0.80 | KMT2A (0.56) | MEN1KMT2ASMN1; SMN2HPGDLMNA | |
| SCHEMBL23303992 | 0.75 | UCHL1 (0.35) | MEN1KMT2AMEP1BTAAR1SMN1; SMN2 | |
| SCHEMBL23286528 | 0.75 | CA2 (0.38) | MEN1KMT2AMEP1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL29825611 | 0.75 | CA2 (0.38) | MEN1KMT2AMEP1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL21468519 | 0.75 | KMT2A (0.39) | MEN1KMT2AMEP1BSMN1; SMN2LMNA | |
| SCHEMBL23088431 | 0.75 | L3MBTL1 (0.42) | MEN1KMT2ASMN1; SMN2HPGDLMNA | |
| SCHEMBL3594266 | 0.74 | MEN1 (0.47) | MEN1KMT2AHPGDALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2021087112-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025892-A1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, CDK1, CDK2 | MEN1 1448/4885KMT2A 1007/4885MEP1B 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.